{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-057435","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2022-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.381020+00:00","generated_at":"2026-06-23T08:36:57.187591+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Pasithea Therapeutics appoints Alfred J. Novak to board; two director changes","bullets":["Dr. Yassine Bendiabdallah resigned from board on Sept 14, 2022, with no disagreement.","Dr. Lawrence Steinman resigned from audit committee, remaining on board and as chair of nominating committee.","Alfred J. Novak appointed to board and audit committee; experienced healthcare executive and former CEO/CFO.","Mr. Novak previously served on boards of Dova Pharmaceuticals (DOVA), LivaNova (LIVN), and others."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-057435","json":"https://secwatch.observer/filing/0001213900-22-057435.json","markdown":"https://secwatch.observer/filing/0001213900-22-057435.md","text":"https://secwatch.observer/filing/0001213900-22-057435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022057435/0001213900-22-057435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022057435/ea165864-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:36:57.187591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c44821738","claim":"Yassine Bendiabdallah resigned as Director at Pasithea Therapeutics Corp..","evidence_excerpt":"On September 14, 2022, Dr. Yassine Bendiabdallah resigned from the board of directors (the “Board”) of Pasithea Therapeutics Corp. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022057435/0001213900-22-057435-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d8f08cc6b4","claim":"Alfred J. Novak was appointed as Director at Pasithea Therapeutics Corp..","evidence_excerpt":"Concurrently, the Board appointed Alfred J. Novak to the Board and to its audit committee.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390022057435/0001213900-22-057435-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}